MedDataX Logo

Pharmacokinetics of Piperacillin and Meropenem in ICU Patients

NCT ID: NCT05134298

Last Updated: 2021-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to characterize the pharmacokinetics of meropenem and piperacillin in ICU-patients at the time of the first dose administration and to contrast that with the same measurements obtained in the same patient 2-3 days later during the course of ICU treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antibiotic Pharmacokinetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Kohort

As specified by study population, inclusion and exclusion criteria

Piperacillin/tazobactam, Meropenem

Intervention Type DRUG

This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Piperacillin/tazobactam, Meropenem

This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patient being treated in one of the participating ICUs and planned to recieve treatment with meropenem or piperacillin.

Exclusion Criteria

* Not possible to retrospectively ask the patient or next of kin for consent to take part in the study or patient or next-of-kin not providing consent.
* Not posisble to obtain and process blood samples as specified by protocol.
* Ongoing renal replacement therapy.
* Patient having received the same antibiotic within the previous 96 h.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Karolinska University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Johan Petersson

Senior ICU consultant, Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Karolinska University Hospital

Stockholm, , Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Johan Petersson, MD, Ass Prof

Role: CONTACT

Phone: +46-8-51770000

Email: [email protected]

Erik Eliasson, MD, Prof

Role: CONTACT

Phone: +46-8-51770000

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Johan Petersson, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K 2018-6443

Identifier Type: -

Identifier Source: org_study_id